1
|
Roach JC, Hara J, Fridman D, Lovejoy JC, Jade K, Heim L, Romansik R, Swietlikowski A, Phillips S, Rapozo MK, Shay MA, Fischer D, Funk C, Dill L, Brant‐Zawadzki M, Hood L, Shankle WR. The Coaching for Cognition in Alzheimer's (COCOA) trial: Study design. A&D Transl Res & Clin Interv 2022; 8:e12318. [PMID: 35910672 PMCID: PMC9322829 DOI: 10.1002/trc2.12318] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/28/2021] [Revised: 05/07/2022] [Accepted: 05/13/2022] [Indexed: 11/15/2022]
Abstract
Comprehensive treatment of Alzheimer's disease (AD) requires not only pharmacologic treatment but also management of existing medical conditions and lifestyle modifications including diet, cognitive training, and exercise. We present the design and methodology for the Coaching for Cognition in Alzheimer's (COCOA) trial. AD and other dementias result from the interplay of multiple interacting dysfunctional biological systems. Monotherapies have had limited success. More interventional studies are needed to test the effectiveness of multimodal multi‐domain therapies for dementia prevention and treatment. Multimodal therapies use multiple interventions to address multiple systemic causes and potentiators of cognitive decline and functional loss; they can be personalized, as different sets of etiologies and systems responsive to therapy may be present in different individuals. COCOA is designed to test the hypothesis that coached multimodal interventions beneficially alter the trajectory of cognitive decline for individuals on the spectrum of AD and related dementias (ADRD). COCOA is a two‐arm prospective randomized controlled trial (RCT). COCOA collects psychometric, clinical, lifestyle, genomic, proteomic, metabolomic, and microbiome data at multiple timepoints across 2 years for each participant. These data enable systems biology analyses. One arm receives standard of care and generic healthy aging recommendations. The other arm receives standard of care and personalized data‐driven remote coaching. The primary outcome measure is the Memory Performance Index (MPI), a measure of cognition. The MPI is a summary statistic of the MCI Screen (MCIS). Secondary outcome measures include the Functional Assessment Staging Test (FAST), a measure of function. COCOA began enrollment in January 2018. We hypothesize that multimodal interventions will ameliorate cognitive decline and that data‐driven health coaching will increase compliance, assist in personalizing multimodal interventions, and improve outcomes for patients, particularly for those in the early stages of the AD spectrum.
Collapse
Affiliation(s)
| | - Junko Hara
- Pickup Family Neurosciences Institute Hoag Memorial Hospital Presbyterian Newport Beach California USA
| | - Deborah Fridman
- Hoag Center for Research and Education Hoag Memorial Hospital Presbyterian Newport Beach California USA
| | | | - Kathleen Jade
- Institute for Systems Biology Seattle Washington USA
| | - Laura Heim
- Hoag Center for Research and Education Hoag Memorial Hospital Presbyterian Newport Beach California USA
| | - Rachel Romansik
- Hoag Center for Research and Education Hoag Memorial Hospital Presbyterian Newport Beach California USA
| | - Adrienne Swietlikowski
- Hoag Center for Research and Education Hoag Memorial Hospital Presbyterian Newport Beach California USA
| | - Sheree Phillips
- Hoag Center for Research and Education Hoag Memorial Hospital Presbyterian Newport Beach California USA
| | | | - Maria A. Shay
- Institute for Systems Biology Seattle Washington USA
| | - Dan Fischer
- Institute for Systems Biology Seattle Washington USA
- Oregon Health & Science University Portland Oregon USA
| | - Cory Funk
- Institute for Systems Biology Seattle Washington USA
| | - Lauren Dill
- Pickup Family Neurosciences Institute Hoag Memorial Hospital Presbyterian Newport Beach California USA
- VA Long Beach Healthcare System Long Beach California USA
| | - Michael Brant‐Zawadzki
- Pickup Family Neurosciences Institute Hoag Memorial Hospital Presbyterian Newport Beach California USA
| | - Leroy Hood
- Institute for Systems Biology Seattle Washington USA
- Providence St. Joseph Health Renton Washington USA
| | - William R. Shankle
- Pickup Family Neurosciences Institute Hoag Memorial Hospital Presbyterian Newport Beach California USA
- Department of Cognitive Sciences University of California Irvine California USA
- Shankle Clinic Newport Beach California USA
- EMBIC Corporation Newport Beach California USA
| |
Collapse
|
2
|
Brant-Zawadzki M, Fridman D, Robinson PA, Zahn M, Chau C, German R, Breit M, Burke E, Bock JR, Hara J. Prevalence and Longevity of SARS-CoV-2 Antibodies Among Health Care Workers. Open Forum Infect Dis 2021; 8:ofab015. [PMID: 33604403 PMCID: PMC7880269 DOI: 10.1093/ofid/ofab015] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2020] [Accepted: 01/14/2021] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Understanding severe acute respiratory syndrome coronavirus 2 antibody prevalence in a spectrum of health care workers (HCWs) may provide benchmarks of susceptibility, help us understand risk stratification, and support enactment of better health policies and procedures. METHODS Blood serum was sampled at enrollment and 8-week follow-up from HCWs (n = 3458) and from community first responders (n = 226) for immunoglobulin G (IgG) analyses. Demographics, job duties, location, and coronavirus disease 2019-related information were collected. RESULTS The observed IgG antibody prevalence was 0.93% and 2.58% at enrollment (May/June) and 8-week follow-up (July/August), respectively, for HCWs, and 5.31% and 4.35% for first responders. For HCWs, significant differences (P < .05) between negative and positive at initial assessment were found for age, race, fever, and loss of smell, and at 8-week follow-up for age, race, and all symptoms. Antibody positivity persisted at least 8 weeks in all positive HCWs. CONCLUSIONS We found considerably lower antibody prevalence among HCWs compared with other published studies. While rigorous safety process measures instituted in our workplace and heightened awareness at and outside of the workplace among our HCWs may have contributed to our findings, the significant discrepancy from our community prevalence warrants further studies on other contributing factors.
Collapse
Affiliation(s)
- Michael Brant-Zawadzki
- Hoag Center for Research and Education, Hoag Memorial Hospital Presbyterian, Newport Beach, California, USA
| | - Deborah Fridman
- Hoag Center for Research and Education, Hoag Memorial Hospital Presbyterian, Newport Beach, California, USA
| | - Philip A Robinson
- Infection Prevention, Hoag Memorial Hospital Presbyterian, Newport Beach, California, USA
| | - Matthew Zahn
- Orange County Health Care Agency, Santa Ana, California, USA
| | - Clayton Chau
- Orange County Health Care Agency, Santa Ana, California, USA
| | - Randy German
- Laboratory Administrative Services, Hoag Memorial Hospital Presbyterian, Newport Beach, California, USA
| | - Marcus Breit
- Hoag Family Cancer Institute, Hoag Memorial Hospital Presbyterian, Newport Beach, California, USA
| | - Elmira Burke
- Quality Management, Hoag Memorial Hospital Presbyterian, Newport Beach, California, USA
| | - Jason R Bock
- Medical Care Corporation, Newport Beach, California, USA
| | - Junko Hara
- Hoag Center for Research and Education, Hoag Memorial Hospital Presbyterian, Newport Beach, California, USA
- Medical Care Corporation, Newport Beach, California, USA
| |
Collapse
|
3
|
Brant-Zawadzki M, Fridman D, Robinson PA, Zahn M, Chau C, German R, Breit M, Bock JR, Hara J. SARS-CoV-2 antibody prevalence in health care workers: Preliminary report of a single center study. PLoS One 2020; 15:e0240006. [PMID: 33180782 PMCID: PMC7660494 DOI: 10.1371/journal.pone.0240006] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2020] [Accepted: 09/17/2020] [Indexed: 12/24/2022] Open
Abstract
Serological surveys have been conducted to establish prevalence for COVID-19 antibodies in various cohorts and communities, reporting a wide range of outcomes. The prevalence of such antibodies among healthcare workers, presumed at higher risk for infection, has been increasingly investigated, more studies are needed to better understand the risks and infection transmission in different healthcare settings. The present study reports on initial sero-surveillance conducted on healthcare workers at a regional hospital system in Orange County, California, during May and June, 2020. Study subjects were recruited from the entire hospital employee workforce and the independent medical staff. Data were collected for job duties and locations, COVID-19 symptoms, a PCR test history, travel record since January 2020, and existence of household contacts with COVID-19. A blood sample was collected from each subject for serum analysis for IgG antibodies to SARS-CoV-2. Of 2,992 tested individuals, a total 2,924 with complete data were included in the analysis. Observed prevalence of 1.06% (31 antibody positive cases), adjusted prevalence of 1.13% for test sensitivity and specificity were identified. Significant group differences between positive vs. negative were observed for age (z = 2.65, p = .008), race (p = .037), presence of fever (p < .001), and loss of smell (p < .001), but not for occupations (p = .710). Possible explanation for this low prevalence includes a relatively low local geographic community prevalence (~4.4%) at the time of testing, the hospital's timely procurement of personal protective equipment, rigorous employee education, patient triage, and treatment protocol development and implementation. In addition, cross-reactive adaptive T cell mediated immunity, as recently described, may possibly play a greater role in healthcare workers than in the general population.
Collapse
Affiliation(s)
- Michael Brant-Zawadzki
- Hoag Center for Research and Education, Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States of America
| | - Deborah Fridman
- Hoag Center for Research and Education, Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States of America
| | - Philip A. Robinson
- Infection Prevention, Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States of America
| | - Matthew Zahn
- Orange County Health Care Agency, Santa Ana, California, United States of America
| | - Clayton Chau
- Orange County Health Care Agency, Santa Ana, California, United States of America
| | - Randy German
- Laboratory Administrative Services, Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States of America
| | - Marcus Breit
- Hoag Family Cancer Institute, Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States of America
| | - Jason R. Bock
- Medical Care Corporation, Newport Beach, California, United States of America
| | - Junko Hara
- Hoag Center for Research and Education, Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States of America
- Medical Care Corporation, Newport Beach, California, United States of America
| |
Collapse
|
4
|
Meljen V, Al-Shibli N, Fridman D. Diagnosis and Management of Vaginal Foreign Body in the Pediatric Patient Using Vaginoscopy: A Case Report. J Minim Invasive Gynecol 2020. [DOI: 10.1016/j.jmig.2020.08.189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
5
|
Bowen TJ, Stephens L, Vance M, Huang Y, Fridman D, Nabhan C. Novel artificial intelligence (AI)-based technology to improve oncology clinical trial fulfillment. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.2052] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2052 Background: Less than 5% of US adult cancer pts are enrolled on clinical trials. Challenges in clinical trial fulfillment limit available treatment options, slow enrollment and ultimately delay new therapies from reaching market. Pt screening requires multiple clinical team members to find pts that meet strict inclusion/exclusion criteria. We evaluated the impact of new technology, Deep Lens VIPER, in identifying more qualified pts for clinical studies, and reduction of staff burden. Methods: We implemented Deep Lens VIPER at Hoag Hospital (Newport Beach, California), accessing the electronic medical records and pathology systems (EMR/LIS) to effectively identify pts who are candidates for 20 ongoing recruiting clinical studies. VIPER was fed pt data from 5,706 surgical pathology pts over a 4-month period (October 1, 2019 - January 31, 2020). Proprietary AI identification and matching technology was configured to align cancer pts with those 20 clinical studies, each with unique study criteria. Following an initial machine-assisted triage step, a research coordinator was alerted when pts who met protocol criteria were ready for final approval steps. Results were analyzed and a qualitative assessment of usability was also performed. Results: VIPER was able to triage all 5,706 surgical pathology cases (100%), identifying 1,045 pts (18.3%) with malignant neoplasms that would qualify for further analysis for clinical trials enrollment. Further triage based on inclusion and exclusion criteria led to the identification of 150 previously unidentified pts for 16 of the 20 studies. The 16 different studies for which potential pts were identified, included 11 tumor types, 12 biomarkers and 3 basket studies. Working with the VIPER system, 1 novice care team member performed initial identification of all 150 previously unidentified pts. The VIPER system increased monthly candidate pt catchment for 16 of the 20 studies under investigation, which is approximately 600 patients annually added for final triage for studies being conducted. Conclusions: We demonstrate the use of an AI-based platform to identify pts for clinical trial enrollment who would be missed using traditional recruiting methods. One staff member effectively triaged participants from 20 different studies with unique inclusion/exclusion criteria. These studies were previously managed by 6 different care team members with limited time for recruitment. Scaling this platform to additional institutions and more studies is ongoing to validate these findings.
Collapse
|
6
|
Rotenberg O, Fridman D, Doulaveris G, Renz M, Kaplan J, Gebb J, Xie X, Goldberg GL, Dar P. Long-term outcome of postmenopausal women with non-atypical endometrial hyperplasia on endometrial sampling. Ultrasound Obstet Gynecol 2020; 55:546-551. [PMID: 31389091 DOI: 10.1002/uog.20421] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/24/2019] [Revised: 07/15/2019] [Accepted: 07/26/2019] [Indexed: 06/10/2023]
Abstract
OBJECTIVE To assess the long-term outcome of postmenopausal women diagnosed with non-atypical endometrial hyperplasia (NEH). METHODS This was a retrospective study of women aged 55 or older who underwent endometrial sampling in our academic medical center between 1997 and 2008. Women who had a current or recent (< 2 years) histological diagnosis of NEH were included in the study group and were compared with those diagnosed with atrophic endometrium (AE). Outcome data were obtained until February 2018. The main outcomes were risk of progression to endometrial carcinoma and risk of persistence, recurrence or new development of endometrial hyperplasia (EH) ('persistent EH'). Logistic regression analysis was used to identify covariates that were independent risk factors for progression to endometrial cancer or persistent EH. RESULTS During the study period, 1808 women aged 55 or older underwent endometrial sampling. The median surveillance time was 10.0 years. Seventy-two women were found to have a current or recent diagnosis of NEH and were compared with 722 women with AE. When compared to women with AE, women with NEH had significantly higher body mass index (33.9 kg/m2 vs 30.6 kg/m2 ; P = 0.01), greater endometrial thickness (10.00 mm vs 6.00 mm; P = 0.01) and higher rates of progression to type-1 endometrial cancer (8.3% vs 0.8%; P = 0.0003) and persistent NEH (22.2% vs 0.7%; P < 0.0001). They also had a higher rate of progression to any type of uterine cancer or persistent EH (33.3% vs 3.5%; P < 0.0001). Women with NEH had a significantly higher rate of future surgical intervention (51.4% vs 15.8%; P < 0.0001), including future hysterectomy (34.7% vs 9.8%; P < 0.0001). On multivariable logistic regression analysis, only NEH remained a significant risk factor for progression to endometrial cancer or persistence of EH. CONCLUSIONS Postmenopausal women with NEH are at significant risk for persistent EH and progression to endometrial cancer, at rates higher than those reported previously. Guidelines for the appropriate management of postmenopausal women with NEH are needed in order to decrease the rate of persistent disease or progression to cancer. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
Collapse
Affiliation(s)
- O Rotenberg
- Department of Obstetrics and Gynecology and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Canter, Bronx, New York, NY, USA
| | - D Fridman
- Department of Obstetrics and Gynecology, Duke University, Durham, NC, USA
| | - G Doulaveris
- Department of Obstetrics and Gynecology and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Canter, Bronx, New York, NY, USA
| | - M Renz
- Department of Obstetrics and Gynecology, Gynecologic Oncology, Stanford University, Stanford, CA, USA
| | - J Kaplan
- Department of Obstetrics and Gynecology and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Canter, Bronx, New York, NY, USA
| | - J Gebb
- Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA
| | - X Xie
- Department of Obstetrics and Gynecology and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Canter, Bronx, New York, NY, USA
| | - G L Goldberg
- Department of Obstetrics and Gynecology, Gynecologic Oncology, Northwell Health, LIJ Medical Center, New Hyde Park, New York, NY, USA
| | - P Dar
- Department of Obstetrics and Gynecology and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Canter, Bronx, New York, NY, USA
| |
Collapse
|
7
|
Momcilovic M, Lee J, Braas D, Graeber T, Parlati F, Demo S, Li R, Gricowski M, Shuman R, Ibarra J, Fridman D, St.John M, Bernthal N, Federman N, Yanagawa J, Dubinett S, Sadeghi S, Christofk H, Shackelford D. B02 The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma. J Thorac Oncol 2020. [DOI: 10.1016/j.jtho.2019.12.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
8
|
Badu A, Wang A, Schwartz MA, Wu CZ, Levie MD, Rotenberg O, Chudnoff SG, Dar P, Fridman D. 2566 Timing of Surgical Intervention Following Failed Medical Management of Ectopic Pregnancy. J Minim Invasive Gynecol 2019. [DOI: 10.1016/j.jmig.2019.09.223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Roach JC, Hara J, Lovejoy JC, Fridman D, Funk C, Heath LM, Price ND, Hood L, Heim L, Brant-Zawadski M, Shankle WR. P4-017: COACHING FOR COGNITION IN ALZHEIMER'S (COCOA) TRIAL. Alzheimers Dement 2019. [DOI: 10.1016/j.jalz.2019.06.3676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
| | - Junko Hara
- Medical Care Corporation; Newport Beach CA USA
- Hoag Memorial Hospital Presbyterian; Newport Beach CA USA
| | | | | | - Cory Funk
- Institute for Systems Biology; Seattle WA USA
| | | | | | - Leroy Hood
- Institute for Systems Biology; Seattle WA USA
| | - Laura Heim
- Hoag Memorial Hospital Presbyterian; Newport Beach CA USA
| | | | - William R. Shankle
- Medical Care Corporation; Newport Beach CA USA
- Hoag Memorial Hospital Presbyterian; Newport Beach CA USA
- Shankle Clinic; Newport Beach CA USA
- University of California at Irvine; Irvine CA USA
| |
Collapse
|
10
|
Wang A, Levie M, Dar P, Rotenberg O, Chudnoff S, Fridman D. Is Surgical Management Still the Main Approach in Treatment of Patients with Probable Ectopic Pregnancy? J Minim Invasive Gynecol 2018. [DOI: 10.1016/j.jmig.2018.09.330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Lopardo G, Vizzotti C, Giglio N, Raimondo E, Fridman D, Micone P, Gonzalez M, Stamboulian D. High effectiveness of PCV13 Vaccine to Prevent Community-Acquired Pneumonia in Adults over 65. Int J Infect Dis 2018. [DOI: 10.1016/j.ijid.2018.04.4218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
12
|
Cisneros V, Fridman D, Lopardo G. Effectiveness of initial antibiotic therapy with beta-lactams VS beta-lactams plus macrolides for adults with community-acquired pneumonia. Int J Infect Dis 2018. [DOI: 10.1016/j.ijid.2018.04.3755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
13
|
Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Braas D, Go J, Graeber TG, Parlati F, Demo S, Li R, Walser TC, Gricowski M, Shuman R, Ibarra J, Fridman D, Phelps ME, Badran K, St John M, Bernthal NM, Federman N, Yanagawa J, Dubinett SM, Sadeghi S, Christofk HR, Shackelford DB. The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma. Cancer Cell 2018; 33:905-921.e5. [PMID: 29763624 PMCID: PMC6451645 DOI: 10.1016/j.ccell.2018.04.002] [Citation(s) in RCA: 123] [Impact Index Per Article: 20.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/21/2017] [Revised: 01/17/2018] [Accepted: 04/05/2018] [Indexed: 12/20/2022]
Abstract
Altered metabolism is a hallmark of cancer growth, forming the conceptual basis for development of metabolic therapies as cancer treatments. We performed in vivo metabolic profiling and molecular analysis of lung squamous cell carcinoma (SCC) to identify metabolic nodes for therapeutic targeting. Lung SCCs adapt to chronic mTOR inhibition and suppression of glycolysis through the GSK3α/β signaling pathway, which upregulates glutaminolysis. Phospho-GSK3α/β protein levels are predictive of response to single-therapy mTOR inhibition while combinatorial treatment with the glutaminase inhibitor CB-839 effectively overcomes therapy resistance. In addition, we identified a conserved metabolic signature in a broad spectrum of hypermetabolic human tumors that may be predictive of patient outcome and response to combined metabolic therapies targeting mTOR and glutaminase.
Collapse
Affiliation(s)
- Milica Momcilovic
- Department of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Sean T Bailey
- Department of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Jason T Lee
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Michael C Fishbein
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Daniel Braas
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; UCLA Metabolomics Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - James Go
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Thomas G Graeber
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; UCLA Metabolomics Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | | | - Susan Demo
- Calithera Biosciences, South San Francisco, CA 94080, USA
| | - Rui Li
- Department of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Tonya C Walser
- Department of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | | | - Robert Shuman
- Memorial Care Health System, Long Beach, CA 90806, USA
| | - Julio Ibarra
- Memorial Care Health System, Long Beach, CA 90806, USA
| | - Deborah Fridman
- Hoag Memorial Hospital Presbyterian, Newport Beach, CA 92663, USA
| | - Michael E Phelps
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Karam Badran
- Department of Head and Neck Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Maie St John
- Department of Head and Neck Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Nicholas M Bernthal
- Department of Orthopedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Noah Federman
- Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Jane Yanagawa
- Department of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Department of Thoracic Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Steven M Dubinett
- Department of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Saman Sadeghi
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Heather R Christofk
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; UCLA Metabolomics Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Department of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - David B Shackelford
- Department of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
| |
Collapse
|
14
|
Wang A, Fridman D, Wu C, Rotenberg O, Dar P, Levie M. Is There a Difference in Presentation of Patients with Recurrent Ectopic Pregnancies? J Minim Invasive Gynecol 2017. [DOI: 10.1016/j.jmig.2017.08.567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
15
|
Fridman D, Chong W, Rotenberg O, Dar P, Mehta S, Hawkins E, Chudnoff S, Levie M. 28: Administration of methotrexate to patients with intrauterine pregnancies misdiagnosed as ectopic. Am J Obstet Gynecol 2017. [DOI: 10.1016/j.ajog.2016.12.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
16
|
Schwartz M, Wu C, Fridman D, Rotenberg O, Arabkhazaeli M, Scott C, Levie M. Why We Fail. Single Dose Methotrexate Failure – Comparing Patients Receiving Second Dose with Those Selected for Surgical Intervention. J Minim Invasive Gynecol 2016. [DOI: 10.1016/j.jmig.2016.08.195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
17
|
Wu C, Fridman D, Rotenberg O, Scott C, Levie M. Comparing Patients with Ectopic Pregnancy Who Fail Methotrexate Therapy with Those Selected for Immediate Surgical Intervention. J Minim Invasive Gynecol 2016. [DOI: 10.1016/j.jmig.2016.08.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
Mehta S, Schwartz M, Fridman D, Levie M, To J, Chudnoff S. Office Hysteroscopy for the Removal of a Retained Intrauterine Device. J Minim Invasive Gynecol 2015; 22:S183. [DOI: 10.1016/j.jmig.2015.08.673] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
19
|
Chong W, Fridman D, Rotenberg O, Hawkins E, Mehta S, Chudnoff S, Levie M. Factors Predicting the Success Rate of a Single Dose of Systemic Methotrexate for the Treatment of Ectopic Pregnancy. J Minim Invasive Gynecol 2015; 22:S89-S90. [DOI: 10.1016/j.jmig.2015.08.241] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
20
|
Fridman D, Chong W, Rotenberg O, Chudnoff S, Hawkins E, Mehta S, Levie M. Compliance With Follow-Up Among Patients Treated With Methotrexate for Suspected Ectopic Pregnancy in an Urban Community Setting. J Minim Invasive Gynecol 2015; 22:S158. [DOI: 10.1016/j.jmig.2015.08.597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
21
|
Chudnoff S, Levie M, Hawkins E, Fridman D. Prospective Clinical Trial Comparing Office Endosee Hysteroscopic Directed Biopsy to Pipelle Endometrial Biopsy. J Minim Invasive Gynecol 2014. [DOI: 10.1016/j.jmig.2014.08.596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
22
|
Wagner J, Saraf S, Fridman D. A Simplified Standardized Technique for LESS (Laparoendoscopic Single Site Surgery) Hysterectomy: Experience with over 300 Cases. J Minim Invasive Gynecol 2013. [DOI: 10.1016/j.jmig.2013.08.533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
23
|
Lopardo G, Fridman D, Gonzalez Arzac M, Calmaggi A, Smayevsky J, Podesta O, Clara L. Uropathogen Resistance: Are Laboratory-Generated Data Reliable Enough? J Chemother 2013; 19:33-7. [PMID: 17309848 DOI: 10.1179/joc.2007.19.1.33] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Therapy of uncomplicated urinary tract infection (UTI) is based on knowledge of in vitro susceptibility profiles of uropathogens in the geographic region. Microbiological surveillance systems, which lack epidemiological and clinical data to differentiate between complicated and uncomplicated UTI may incorrectly estimate rates of resistance in the community. We determined the susceptibility profile of bacteria isolated from a random sample of 124 adult outpatients with diagnosis of uncomplicated UTI and we compared it with all outpatient urine specimens collected by the same participant laboratories during the same period. Escherichia coli was the most frequently isolated uropathogen in patients with uncomplicated UTI, and its rate of resistance to different antimicrobials was lower than overall resistance rates to E. coli reported by the participating laboratories during the same period. Resistance to cotrimoxazole was significantly lower. These results suggest that surveillance systems without clinical and epidemiological data may incorrectly gauge uropathogen resistance in the community.
Collapse
Affiliation(s)
- G Lopardo
- Sociedad Argentina de Infectología, Buenos Aires, Argentina.
| | | | | | | | | | | | | |
Collapse
|
24
|
Saraf S, Fridman D, Wagner J. Single-Incision Laparoscopic Gynecological Surgeries: 1 Year Experience. J Minim Invasive Gynecol 2011. [DOI: 10.1016/j.jmig.2011.08.555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
25
|
Fridman D, Saraf S, Wagner J. Single-Incision Laparoscopy as the Primary Approach to Benign Hysterectomy: One Year Experience. J Minim Invasive Gynecol 2011. [DOI: 10.1016/j.jmig.2011.08.112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
26
|
Altman H, Steinberg D, Porat Y, Mor A, Fridman D, Friedman M, Bachrach G. In vitro assessment of antimicrobial peptides as potential agents against several oral bacteria. J Antimicrob Chemother 2006; 58:198-201. [PMID: 16687459 DOI: 10.1093/jac/dkl181] [Citation(s) in RCA: 92] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Antimicrobial peptides are components of the innate immunity that play an important role in systemic and oral health. OBJECTIVES The antibacterial activity of the amphibian-derived K4 -S4(1-15)a antimicrobial peptide was tested against oral pathogens associated with caries and periodontitis and compared with the activities of the human-derived antimicrobial peptides LL-37 and dhvar4a. METHODS Growth inhibition of planktonic bacteria was tested using standard microdilution assays. Live/Dead staining followed by confocal scanning laser microscopy (CSLM) was used to determine the bactericidal effect of K4 -S4(1-15)a on Streptococcus mutans attached to a glass surface or grown as biofilm. RESULTS The cariogenic species S. mutans, Streptococcus sobrinus, Lactobacillus paracasei and Actinomyces viscosus were resistant to LL-37 found in the oral cavity. Porphyromonas gingivalis was the species most resistant to the three tested peptides. K4 -S4(1-15)a demonstrated the highest activity against the tested planktonic bacteria. In addition, K4 -S4(1-15)a was bactericidal to surface-attached S. mutans as well as to S. mutans biofilms grown in vitro. However, surface attachment increased S. mutans resistance to the antimicrobial peptide. CONCLUSIONS Our results support growing evidence suggesting the use of antimicrobial peptides for prevention and treatment of oral disease.
Collapse
Affiliation(s)
- H Altman
- Institute of Dental Sciences, Hebrew University-Hadassah School of Dental Medicine, The Hebrew University of Jerusalem Jerusalem, Israel
| | | | | | | | | | | | | |
Collapse
|